Biogen Inc. ($BIIB) Stock Forecast: Down 5.1% Today

What is Biogen Inc.?

Biogen (BIIB) is a renowned biotechnology company known for its innovative treatments in neurology and Alzheimer's disease. Today, the stock experienced a strong bearish movement in the market.

Why is Biogen Inc. going down?

BIIB stock is down 5.1% on Dec 10, 2025 14:40

• Biogen's stock saw a bearish trend despite receiving Health Canada authorization for ZURZUVAE, a groundbreaking treatment for postpartum depression. This unexpected market reaction could be due to various factors:
• The after-hours rally in other biotech stocks, driven by new clinical data and FDA designations, might have shifted investor focus away from Biogen temporarily.
• Highlighting Biogen's undervaluation and potential as a bargain could have already been priced in, leading to profit-taking by investors.
• The market might be reacting to the broader sector movements and investor sentiment rather than solely focusing on Biogen's individual achievements in the postpartum depression treatment space.
• Overall, despite the positive news regarding ZURZUVAE, external factors and profit considerations could have influenced the bearish movement in Biogen's stock today.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Biogen Canada Inc. has received Health Canada authorization for ZURZUVAE™ (zuranolone), making it the first and only oral treatment specifically for moderate to severe postpartum depression (PPD) in adults. ZURZUVAE is a 14-day oral treatment that has shown to provide relief from depressive symptoms as early as Day 3 and sustained effect through Day 45 in clinical trials. This approval addresses a critical unmet need for Canadian mothers, offering a novel therapeutic approach that targets mood dysregulation related to hormonal fluctuations after childbirth.

https://www.biospace.com/press-releases/biogen-receives-health-canada-authorization-for-zurzuvae-zuranolone-the-first-and-only-treatment-indicated-for-adults-with-postpartum-depression-in-canada

After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers

Biotech stocks experienced significant after-hours rallies driven by new clinical data, FDA designations, and financing news. Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways were among the leaders, with several companies rebounding from earlier session losses. These movements highlight key catalysts that are influencing investor interest in the biotech sector.

https://www.nasdaq.com/articles/after-hours-rally-stoke-therapeutics-alpha-tau-medical-compass-pathways-lead-biotech

Is Biogen’s Recent 20% Rally Just the Start as Valuation Signals Turn Attractive?

Biogen (BIIB) has seen a 20% year-to-date rally, driven by re-evaluated sentiment around its neurology and Alzheimer's portfolio. Its valuation scores as undervalued with a 51.1% discount based on Discounted Cash Flow analysis and a Price to Earnings ratio below both industry averages and its proprietary Fair Ratio. The article suggests that despite recent gains, Biogen may still be a bargain according to these metrics.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/is-biogens-recent-20-rally-just-the-start-as-valuation-signa

“Smart” NK Cells: Senti Bio’s Logic-Gated Immunotherapy Strikes R/R AML

Senti Biosciences has developed a "smart" CAR NK cell therapy, SENTI-202, demonstrating promising Phase I clinical data for relapsed/refractory AML (R/R AML). This logic-gated immunotherapy utilizes AND/NOT gates to selectively target cancer cells while sparing healthy tissue, achieving durable remissions and eliminating leukemic stem cells without severe toxicities. The technology aims to overcome limitations of traditional CAR T therapies by enabling precise decision-making within therapeutic cells, with potential expansion to solid tumors.

https://www.insideprecisionmedicine.com/topics/oncology/smart-nk-cells-senti-bios-logic-gated-immunotherapy-strikes-r-r-aml/

Biogen (SUPN) gains Health Canada NOC for ZURZUVAE in postpartum depression treatment

Health Canada has authorized ZURZUVAE (zuranolone) for treating moderate to severe postpartum depression (PPD) in adults, making it the first and only oral, 14-day treatment specifically indicated for PPD in Canada. Clinical studies show ZURZUVAE offers relief from depressive symptoms as early as Day 3, with sustained effects through Day 45. This approval addresses a significant unmet medical need for Canadian mothers, who frequently suffer from PPD, and represents a novel therapeutic approach compared to traditional antidepressants.

https://www.stocktitan.net/news/SUPN/biogen-receives-health-canada-authorization-for-zurzuvaetm-fhi1ykgha2jj.html

Trending Today

Filecoin ($FIL) Crypto Forecast: Up 5.0% Today

PancakeSwap ($CAKE) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.7% Today

Comcast Corporation Class A Common Stock ($CMCSA) Stock Forecast: Up 5.0% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Phillips 66 ($PSX) Stock Forecast: Down 5.1% Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

Biogen Inc. Price History

07.02.2025 - BIIB Stock was up 5.2%

• BIIB stock exhibited a bullish trend despite worries about the pricing of Alzheimer's drugs from Biogen and Eli Lilly.
• Investor optimism towards the potential market demand for Biogen's treatments persists despite pricing concerns.
• The bullish movement reflects confidence in Biogen's capacity to address pricing challenges and advance pioneering therapies in neurology.

31.09.2025 - BIIB Stock was up 3.1%

• BIIB surpassed Q3 earnings and revenue expectations, leading to an initial decline in its stock price following the company's reduction of its 2025 EPS forecast.
• The approval from Health Canada for "LEQEMBI®" to treat early Alzheimer's disease likely contributed to the stock's positive movement.
• Analysts highlighting the potential of Biogen's long-term immunology pipeline, particularly after a recent licensing agreement, may have boosted investor confidence in the company.
• The stock's bullish performance can be attributed to a mix of strong financial results, favorable regulatory milestones, and promising developments in Biogen's product pipeline.

30.09.2025 - BIIB Stock was up 2.3%

• Biogen (BIIB) reported impressive Q3 earnings and revenues, surpassing estimates by a significant margin, indicating strong financial performance.
• Health Canada granting authorization for "LEQEMBI®" for the treatment of Early Alzheimer's Disease is a significant milestone for Biogen, boosting investor confidence in the company's Alzheimer's treatment pipeline.
• The licensing agreement with Vanqua Bio to acquire exclusive rights to a preclinical oral C5aR1 antagonist strengthens Biogen's immunology portfolio, highlighting the company's commitment to innovation and expansion in the healthcare sector.
• The positive news surrounding Biogen's financials, advancements in Alzheimer's treatment, and expansion of its immunology pipeline likely contributed to the bullish movement in the stock today.

01.04.2025 - BIIB Stock was up 3.7%

• BIIB stock surged as investors were impressed by the company's strong performance in the first quarter of 2025.
• Despite Sage Therapeutics' disappointing earnings, BIIB's robust financial results and promising outlook for key metrics exceeded Wall Street estimates, driving up the stock price.
• The market reacted favorably to BIIB's Q1 outlook, indicating confidence in the company's ability to deliver solid results and maintain its position as a key player in the biotech industry.
• Overall, BIIB's bullish movement can be attributed to its strong fundamentals and positive market expectations, contrasting with the underperformance of some of its industry peers.

06.04.2025 - BIIB Stock was down 5.1%

• Following its Q1 earnings release, BIIB witnessed a significant decrease in stock value.
• BIIB outperformed earnings projections, posting an EPS of $3.02 compared to the estimated $2.52, and recorded a revenue surge to $2.43 billion, exceeding the expected $2.23 billion.
• Despite the positive earnings outcome, BIIB's stock faced a decline, potentially due to the mixed Q1 performance and the company's downward revision of its EPS guidance for the year.
• The market response to the revised guidance hints at apprehensions regarding future growth and performance, contributing to the bearish movement in BIIB's stock price today.

04.03.2025 - BIIB Stock was down 5.0%

• BIIB's stock likely dropped due to the positive announcement of its experimental Alzheimer's drug receiving FDA's fast track designation, potentially heightening optimism for its future success.
• Eli Lilly's Alzheimer's drug received a negative assessment from the European Medicines Agency (EMA), indirectly benefitting Biogen by reducing competition in the Alzheimer's treatment sector.
• Investor sentiment appears to favor Biogen over Eli Lilly, given the challenges the latter faces in gaining regulatory approval for its Alzheimer's drug.
• The divergent paths of the two companies in Alzheimer's drug development may have influenced market outlook towards Biogen, contributing to the downward movement in its stock value today.

13.01.2025 - BIIB Stock was up 5.3%

• Biogen reported better-than-expected earnings for its fourth quarter, with adjusted EPS beating consensus estimates.
• Despite the positive earnings report, Biogen's 2025 EPS guidance fell short of expectations, leading to some analyst downgrades.
• The market reacted positively to Biogen's cost-cutting measures and the potential of new drugs like Leqembi, which are expected to offset revenue declines from existing products.
• Overall, the bullish movement in Biogen's stock can be attributed to the company's strong financial performance in Q4, despite some concerns about future earnings guidance.

12.01.2025 - BIIB Stock was down 5.1%

• Despite surpassing earnings and revenue projections in Q4, BIIB experienced a bearish market movement, suggesting potentially elevated market anticipations.
• The projection of profits fell below expectations despite efforts such as cost reductions and the introduction of new medications like Leqembi, indicating possible investor dissatisfaction with the company's future prospects.
• An increase in optimistic positions on BIIB through options trading potentially heightened market volatility and profit-taking, contributing to the downward trend.
• The decrease in sales of multiple sclerosis treatments and Spinraza was balanced by revenues from new drugs, but this may not have met investor expectations, resulting in the bearish market movement.

12.01.2025 - BIIB Stock was down 8.1%

• Biogen exceeded expectations with cost reduction efforts and the launch of Leqembi, but a lower profit outlook caused a decline in the stock price.
• The FDA's approval of a maintenance dosing regimen for Leqembi in Alzheimer's was a positive development, while decreased sales of multiple sclerosis drugs and Spinraza likely impacted revenue.
• Investor optimism in the options market suggests confidence in the long-term potential of Biogen's new drugs, despite short-term profit concerns.
• The forthcoming Q4 earnings report will be essential in offering more insight into the company's financial performance and the effects of new drugs on revenue.

01.07.2025 - BIIB Stock was down 6.0%

• Biogen exceeded earnings and revenue projections for Q2 2025, but its stock faced a downward trend.
• Concerns arose over the drop in sales of MS medications, despite the promising growth exhibited by newer drugs like Leqembi and Skyclarys.
• Investors are exercising caution regarding the company's overall prospects, given the balance between declining sales of MS drugs and gains from newer products.
• While the initial market response to the strong earnings and raised forecasts was positive, uncertainties about Biogen's future performance in the competitive pharmaceutical industry may be dampening investor sentiment.

01.09.2025 - BIIB Stock was up 5.1%

• BIIB stock showed significant growth in trading today.
• The approval of "LEQEMBI®" for Early Alzheimer's Disease treatment in China is believed to have influenced the positive market sentiment.
• Although they received a Complete Response Letter from the FDA for a different drug application, the initiation of bullish coverage by analysts may have outweighed this development.
• Favorable analyst coverage and optimistic forecasts for Biogen likely boosted investor confidence and contributed to the stock's upward trajectory.

10.11.2025 - BIIB Stock was down 5.1%

• Biogen's stock saw a bearish trend despite receiving Health Canada authorization for ZURZUVAE, a groundbreaking treatment for postpartum depression. This unexpected market reaction could be due to various factors:
• The after-hours rally in other biotech stocks, driven by new clinical data and FDA designations, might have shifted investor focus away from Biogen temporarily.
• Highlighting Biogen's undervaluation and potential as a bargain could have already been priced in, leading to profit-taking by investors.
• The market might be reacting to the broader sector movements and investor sentiment rather than solely focusing on Biogen's individual achievements in the postpartum depression treatment space.
• Overall, despite the positive news regarding ZURZUVAE, external factors and profit considerations could have influenced the bearish movement in Biogen's stock today.